Discontinued — last reported Q1 '23
Boston Scientific Supplier Finance Program Obligations increased by 8.6% to $151.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.2%, from $137.00M to $151.00M. Over 2 years (FY 2022 to FY 2024), Supplier Finance Program Obligations shows relatively stable performance with a 4.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may signal aggressive working capital management or a reliance on external financing to delay cash outflows.
This represents amounts owed to suppliers that have been financed through third-party financial institutions, often refe...
Increasingly common in consumer goods, though transparency varies significantly between companies.
supplier_finance_obligations| Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $129.00M | $124.00M | $148.00M | $152.00M | $140.00M | $131.00M | $137.00M | $140.00M | $129.00M | $139.00M | $151.00M |
| QoQ Change | — | -3.9% | +19.4% | +2.7% | -7.9% | -6.4% | +4.6% | +2.2% | -7.9% | +7.8% | +8.6% |
| YoY Change | — | — | — | +17.8% | — | +5.6% | -7.4% | -7.9% | -7.9% | +6.1% | +10.2% |